INTEGrating Ag-RDTs for COVID-19 in MNCH,HIV and TB Services in Cameroon and Kenya

Summary

Integration of antigen-detecting rapid diagnostic tests (Ag-RDT) for COVID-19 into services that provide care for vulnerable populations such as pregnant women, children, people with HIV infection, and patients with tuberculosis (TB) will identify more people with Coronavirus infection. This will allow for earlier treatment and tracing of contacts to decrease the spread of the coronavirus. This study is looking at two models for providing the testing in Maternal, Newborn and Child Health (MNCH), Tuberculosis (TB) and HIV clinics in Cameroon and Kenya. In some clinics, attendees with be screened for Coronavirus symptoms and history of exposure and if positive they will receive the rapid coronavirus test right in the clinic. In other facilities, all people attending the clinic with be provided with the coronavirus testing even if they screen negative to see how many people are infected but do not show any symptoms. Hospitalized and non-hospitalized patients with the coronavirus infection will be followed to document their illness and health outcomes. We will also ask health care workers about how well the testing in these clinics is working and what are some of their challenges, and collect information about the costs associated with both the models of testing.

Conditions

• COVID-19

Interventions

DIAGNOSTIC_TEST

Test all

In the "test all" arm, SARS-CoV-2 infection screening questions will be administered to all clinic attendees followed by SARS-CoV-2 Ag-RDT testing irrespective of screening results.

Sponsors & Collaborators

• UNITAID

  collaborator OTHER

• Kenya Ministry of Health

  collaborator OTHER_GOV

• Ministry of Public Health, Cameroon

  collaborator UNKNOWN

• Elizabeth Glaser Pediatric AIDS Foundation

  lead OTHER

Principal Investigators

• Nilesh Bhatt, MD,MMed,PhD · Elizabeth Glaser Pediatric AIDS Foundation

• Boris Tchounga, MD, PhD · Elizabeth Glaser Pediatric AIDS Foundation

• Rose Otieno Masaba, MD, MSc · Elizabeth Glaser Pediatric AIDS Foundation

Study Design

Allocation

RANDOMIZED

Purpose

OTHER

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

2 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2022-05-17

Primary Completion

2023-03-31

Completion

2023-03-31

Countries

• Cameroon
• Kenya

Study Locations